|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Crystal structure of human coagulation factor xa complexed with rpr208815
|
|
Structure:
|
 |
Coagulation factor xa. Chain: a. Fragment: activated factor xa, heavy chain. Coagulation factor xa. Chain: b. Fragment: factor x light chain. Ec: 3.4.21.6
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Organism_taxid: 9606
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
2.10Å
|
R-factor:
|
0.216
|
R-free:
|
0.263
|
|
|
Authors:
|
 |
S.Maignan,J.P.Guilloteau,S.Pouzieux,Y.M.Choi-Sledeski,M.R.Becker, S.I.Klein,W.R.Ewing,H.W.Pauls,A.P.Spada,V.Mikol
|
|
Key ref:
|
 |
S.Maignan
et al.
(2000).
Crystal structures of human factor Xa complexed with potent inhibitors.
J Med Chem,
43,
3226-3232.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
17-May-00
|
Release date:
|
20-Sep-00
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
Chains A, B:
E.C.3.4.21.6
- coagulation factor Xa.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Preferential cleavage: Arg-|-Thr and then Arg-|-Ile bonds in prothrombin to form thrombin.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Med Chem
43:3226-3232
(2000)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structures of human factor Xa complexed with potent inhibitors.
|
|
S.Maignan,
J.P.Guilloteau,
S.Pouzieux,
Y.M.Choi-Sledeski,
M.R.Becker,
S.I.Klein,
W.R.Ewing,
H.W.Pauls,
A.P.Spada,
V.Mikol.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Involved in the coagulation cascade, factor Xa (FXa) is a serine protease which
has received great interest as a potential target for the development of new
antithrombotics. Although there is a great wealth of structural data on thrombin
complexes, few structures of ligand/FXa complexes have been reported, presumably
because of the difficulty in growing crystals. Reproducible crystallization
conditions for human des-Gla1-45 coagulation FXa have been found. This has led
to an improvement in the diffraction quality of the crystals (about 2.1 A) when
compared to the previously reported forms (2.3-2.8 A) thus providing a suitable
platform for a structure-based drug design approach. A series of crystal
structures of noncovalent inhibitors complexed with FXa have been determined,
three of which are presented herein. These include compounds containing the
benzamidine moiety and surrogates of the basic group. The benzamidine-containing
compound binds in a canonical fashion typical of synthetic serine protease
inhibitors. On the contrary, molecules that contain surrogates of the
benzamidine group do not make direct hydrogen-bonding interactions with the
carboxylate of Asp189 at the bottom of the S1 pocket. The structural data
provide a likely explanation for the specificity of these inhibitors and a great
aid in the design of bioavailable potent FXa inhibitors.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
V.Hähnke,
A.Klenner,
F.Rippmann,
and
G.Schneider
(2011).
Pharmacophore alignment search tool: Influence of the third dimension on text-based similarity searching.
|
| |
J Comput Chem,
32,
1618-1634.
|
 |
|
|
|
|
 |
E.Luttmann,
D.L.Ensign,
V.Vaidyanathan,
M.Houston,
N.Rimon,
J.Øland,
G.Jayachandran,
M.Friedrichs,
and
V.S.Pande
(2009).
Accelerating molecular dynamic simulation on the cell processor and Playstation 3.
|
| |
J Comput Chem,
30,
268-274.
|
 |
|
|
|
|
 |
H.Fan,
J.J.Irwin,
B.M.Webb,
G.Klebe,
B.K.Shoichet,
and
A.Sali
(2009).
Molecular docking screens using comparative models of proteins.
|
| |
J Chem Inf Model,
49,
2512-2527.
|
 |
|
|
|
|
 |
R.Chattopadhyay,
R.Iacob,
S.Sen,
R.Majumder,
K.B.Tomer,
and
B.R.Lentz
(2009).
Functional and structural characterization of factor Xa dimer in solution.
|
| |
Biophys J,
96,
974-986.
|
 |
|
|
|
|
 |
R.Gil-Redondo,
J.Estrada,
A.Morreale,
F.Herranz,
J.Sancho,
and
A.R.Ortiz
(2009).
VSDMIP: virtual screening data management on an integrated platform.
|
| |
J Comput Aided Mol Des,
23,
171-184.
|
 |
|
|
|
|
 |
Y.Tanrikulu,
E.Proschak,
T.Werner,
T.Geppert,
N.Todoroff,
A.Klenner,
T.Kottke,
K.Sander,
E.Schneider,
R.Seifert,
H.Stark,
T.Clark,
and
G.Schneider
(2009).
Homology model adjustment and ligand screening with a pseudoreceptor of the human histamine H4 receptor.
|
| |
ChemMedChem,
4,
820-827.
|
 |
|
|
|
|
 |
E.Proschak,
M.Rupp,
S.Derksen,
and
G.Schneider
(2008).
Shapelets: possibilities and limitations of shape-based virtual screening.
|
| |
J Comput Chem,
29,
108-114.
|
 |
|
|
|
|
 |
N.Singh,
and
J.M.Briggs
(2008).
Molecular dynamics simulations of Factor Xa: insight into conformational transition of its binding subsites.
|
| |
Biopolymers,
89,
1104-1113.
|
 |
|
|
|
|
 |
R.Abel,
T.Young,
R.Farid,
B.J.Berne,
and
R.A.Friesner
(2008).
Role of the active-site solvent in the thermodynamics of factor Xa ligand binding.
|
| |
J Am Chem Soc,
130,
2817-2831.
|
 |
|
|
|
|
 |
Y.Imaeda,
T.Miyawaki,
H.Sakamoto,
F.Itoh,
N.Konishi,
K.Hiroe,
M.Kawamura,
T.Tanaka,
and
K.Kubo
(2008).
Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors.
|
| |
Bioorg Med Chem,
16,
2243-2260.
|
 |
|
|
|
|
 |
A.Di Fenza,
A.Heine,
U.Koert,
and
G.Klebe
(2007).
Understanding Binding Selectivity toward Trypsin and Factor Xa: the Role of Aromatic Interactions.
|
| |
ChemMedChem,
2,
297-308.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.T.Kohrt,
C.F.Bigge,
J.W.Bryant,
A.Casimiro-Garcia,
L.Chi,
W.L.Cody,
T.Dahring,
D.A.Dudley,
K.J.Filipski,
S.Haarer,
R.Heemstra,
N.Janiczek,
L.Narasimhan,
T.McClanahan,
J.T.Peterson,
V.Sahasrabudhe,
R.Schaum,
C.A.Van Huis,
K.M.Welch,
E.Zhang,
R.J.Leadley,
and
J.J.Edmunds
(2007).
The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor.
|
| |
Chem Biol Drug Des,
70,
100-112.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.Noguchi,
N.Tanaka,
T.Nishimata,
R.Goto,
M.Hayakawa,
A.Sugidachi,
T.Ogawa,
F.Asai,
and
K.Fujimoto
(2007).
Cinnamylindoline derivatives: synthesis and factor Xa (FXa) inhibitory activities.
|
| |
Chem Pharm Bull (Tokyo),
55,
1494-1504.
|
 |
|
|
|
|
 |
D.J.Johnson,
W.Li,
T.E.Adams,
and
J.A.Huntington
(2006).
Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation.
|
| |
EMBO J,
25,
2029-2037.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.M.Bromfield,
N.S.Quinsey,
P.J.Duggan,
and
R.N.Pike
(2006).
Approaches to selective peptidic inhibitors of factor Xa.
|
| |
Chem Biol Drug Des,
68,
11-19.
|
 |
|
|
|
|
 |
M.Nayal,
and
B.Honig
(2006).
On the nature of cavities on protein surfaces: application to the identification of drug-binding sites.
|
| |
Proteins,
63,
892-906.
|
 |
|
|
|
|
 |
S.Cotesta,
and
M.Stahl
(2006).
The environment of amide groups in protein-ligand complexes: H-bonds and beyond.
|
| |
J Mol Model,
12,
436-444.
|
 |
|
|
|
|
 |
K.Schärer,
M.Morgenthaler,
R.Paulini,
U.Obst-Sander,
D.W.Banner,
D.Schlatter,
J.Benz,
M.Stihle,
and
F.Diederich
(2005).
Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of Factor Xa bound to a quaternary ammonium ion ligand.
|
| |
Angew Chem Int Ed Engl,
44,
4400-4404.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
H.K.Leiros,
B.O.Brandsdal,
O.A.Andersen,
V.Os,
I.Leiros,
R.Helland,
J.Otlewski,
N.P.Willassen,
and
A.O.Smalås
(2004).
Trypsin specificity as elucidated by LIE calculations, X-ray structures, and association constant measurements.
|
| |
Protein Sci,
13,
1056-1070.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.Oostenbrink,
and
W.F.van Gunsteren
(2003).
Single-step perturbations to calculate free energy differences from unphysical reference states: limits on size, flexibility, and character.
|
| |
J Comput Chem,
24,
1730-1739.
|
 |
|
|
|
|
 |
J.P.Ludeman,
R.N.Pike,
K.M.Bromfield,
P.J.Duggan,
J.Cianci,
B.Le Bonniec,
J.C.Whisstock,
and
S.P.Bottomley
(2003).
Determination of the P1', P2' and P3' subsite-specificity of factor Xa.
|
| |
Int J Biochem Cell Biol,
35,
221-225.
|
 |
|
|
|
|
 |
D.Rauh,
S.Reyda,
G.Klebe,
and
M.T.Stubbs
(2002).
Trypsin mutants for structure-based drug design: expression, refolding and crystallisation.
|
| |
Biol Chem,
383,
1309-1314.
|
 |
|
|
|
|
 |
N.S.Quinsey,
J.C.Whisstock,
B.Le Bonniec,
V.Louvain,
S.P.Bottomley,
and
R.N.Pike
(2002).
Molecular determinants of the mechanism underlying acceleration of the interaction between antithrombin and factor Xa by heparin pentasaccharide.
|
| |
J Biol Chem,
277,
15971-15978.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |